Role of high dose rate interstitial brachytherapy in early and locally advanced squamous cell carcinoma of buccal mucosa by Parthasarathy Vedasoundaram et al.
a SpringerOpen Journal
Vedasoundaram et al. SpringerPlus 2014, 3:590
http://www.springerplus.com/content/3/1/590RESEARCH Open AccessRole of high dose rate interstitial brachytherapy
in early and locally advanced squamous cell
carcinoma of buccal mucosa
Parthasarathy Vedasoundaram1*, Aravind Kumar Prasanna1, Reddy KS1, Gangothri Selvarajan1,
Mourougan Sinnatamby2, Seenisamy Ramapandian2 and Saravanan Kandasamy2Abstract
Background: The study aimed to assess the effect of High Dose Rate (HDR) Interstitial Brachytherapy when used
alone or in combination with External Beam Radiotherapy (EBRT), in early and locally advanced squamous cell
carcinoma of buccal mucosa.
Materials and methods: Thirty three patients with histologically proven squamous cell carcinoma of the buccal
mucosa received high dose rate interstitial brachytherapy either as primary treatment or as a boost from November
2008 to April 2013. Stage I patients received interstitial brachytherapy alone to a dose of 38.50 Gy, 3.5 Gy per
fraction, twice daily at six hours apart for 11 fractions. Stage II patients received EBRT to a dose of 50 Gy in 25
fractions of two Gy each followed by brachytherapy boost to 21 Gy, 3.5 Gy per fraction, twice daily at six hours
apart for six fractions. Stage III patients received the same radiotherapy schedule (i.e., same EBRT & Brachytherapy
schedule) and with addition of Injection Cisplatin 70 mg/m2 in three divided doses every three weeks along with
EBRT.
Results: Follow up ranged from 12 to 60 months, median follow up was 26 months. Complete response was
observed in 28 patients. Five patients had residual disease and were referred for surgical salvage. One patient died
of disease progression. Stage I patients had 100% local control, whereas Stage II and Stage III patients had 84.6%
and 80% local control respectively.
Conclusion: HDR Interstitial Brachytherapy used either as a primary treatment modality or as a boost in buccal
mucosal cancers provides results comparable to that of surgery, with the advantages of organ preservation, better
cosmetic and functional outcomes.
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Brachytherapy has been used in the management of can-
cers since the advent of radiotherapy as a treatment mo-
dality in Oncology. It has proven its utility in the treatment
of localized tumors with its ability to provide high doses to
the target volume while sparing the surrounding normal
tissues due to its rapid dose fall-off. This has enabled
brachytherapy to be an efficient and cost effective form of* Correspondence: dr_patchu2003@yahoo.co.in
1Radiation Oncologists, Department of Radiotherapy, Regional Cancer Center,
Jawaharlal Institute of Postgraduate Medical Education and Research, JIPMER,
Puducherry – 6, Puducherry, India
Full list of author information is available at the end of the article
© 2014 Vedasoundaram et al.; licensee Springe
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origconformal radiation therapy, now widely utilized as a
significant component of the standard treatment modality
in specific cancers including that of cervix, prostate, breast,
head and neck, etc., (Mazeron et al. 2003).
Surgery has been the primary modality of treatment in
early T1 &T2 buccal mucosal cancers. However, with
comparatively better cosmetic and functional outcomes,
similar local control and survival figures, radiotherapy
has become a preferred alternative to surgery and is rec-
ommended by the current NCCN guidelines as a standa-
lone treatment option in these cancers. Brachytherapy
alone can be used in the treatment of specific T1N0r. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Table 1 Patient’s profile
Distribution Number Percent
Number of patients 33




Tobacco chewing 21 63.63
Smoking 18 54.54
Alcohol 11 33.33
Betel nut chewing 21 63.63
None 2 6.06
Tumor growth characteristics
Infiltrative disease 17 51.51
Proliferative disease 13 39.39
Both 3 9.09
Disease status and treatment
T1 Disease 5 15.15
T2 Disease 16 48.48
T3 Disease 12 36.36
N0 28 84.84
N1 5 15.15
Stage 1 5 15.15
Stage II 13 39.4
Stage III 15 45.45
EBRT 13 39.39
CCRT 15 45.45
Abbreviations: EBRT External beam radiotherapy, CCRT Concurrent
Chemo Radiotherapy.
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et al. 2004; Pernot et al. 1995).
Though Surgery with post-operative radiotherapy has
been standard approach for locally advanced head and
neck cancers, concurrent chemotherapy with radiotherapy
can be an alternative according to recent NCCN guide-
lines 2014, but the role of brachytherapy boost is yet to be
defined. EBRT with HDR brachytherapy boost has been
shown to provide better local control rates compared to
external beam radiation alone in locally advanced oral
cavity cancers (Donath et al. 1995). Also, concurrent
chemo radiation with Injection Cisplatin has proven its
superiority over radiotherapy alone in locally advanced
head and neck cancers (Studer et al. 2007). However, very
few studies have utilized concurrent chemo radiation with
brachytherapy boost in these situations.
Various forms of brachytherapy applications including
interstitial implants, stents, and molds have been used to
treat buccal mucosal cancers (Friedrich et al. 1995; Yoden
et al. 1999; Ngan et al. 2005). Most of the earlier studies
in these cases have been done using Low Dose Rate
(LDR) brachytherapy (Conill et al. 2007). In this study
HDR brachytherapy with Iridium 192 source, remotely
after loaded via flexible catheters implanted interstitially
in the tumor was used. The purpose of this study was to
investigate the utility and benefit of brachytherapy with
or without EBRT as the sole modality of treatment in
early buccal mucosal cancers and as a part of concur-
rent chemo radiation in locally advanced tumors, in
Indian patients.
Materials and methods
The study included 33 patients with histologically proven
squamous cell carcinomas of the buccal mucosa who
attended the outpatient department of the Regional
Cancer Centre in Jawaharlal Institute of Postgraduate
Medical Education & Research (JIPMER) Hospital,
Puducherry, from November 2008 to April 2013. Of
these, 19 were males and 14 females, with ages ranging
from 39 to 65 years (Mean – 52.85 years). Only pa-
tients with T1-T3/N0-N1 stage cancers and ECOG
performance scores with 0,1or 2 were recruited for the
study. Table 1 shows a summary of the patient profiles
according to age, gender, performance status, habits,
tumor stage and growth pattern.
Complete staging workup including thorough physical
examination, biopsy of the primary site, Fine Needle As-
piration Cytology (FNAC) of clinically identified lymph
nodes, Chest X-ray, Contrast Enhanced Computed Tom-
ography (CECT) scan of head and neck if needed, and
baseline blood counts and biochemistry were done for
all the patients. Anesthetic fitness was obtained for the
brachytherapy procedure. All patients were staged using
American Joint Committee on Cancer (AJCC) - 7th Editionrecommendations and treatments provided accordingly
(Sobin et al. 2009).
Treatment protocol, planning and implementation
Primary brachytherapy alone was considered for treat-
ment in five patients with Stage I disease. They received
interstitial brachytherapy at a dose of 3.5 Gy per frac-
tion, two fractions per day at six hours apart for 11 frac-
tions, to a total dose of 3850 cGy. 13 patients with Stage
II disease received EBRT and brachytherapy boost, EBRT
was delivered to a dose of 50 Gy in 25 fractions of two
Gy each, five fractions per week for 5 weeks. Brachyther-
apy boost dose was 21 Gy given in six fractions of 3.5 Gy
each, twice daily at 6 hours apart, given within two to four
weeks of EBRT. 15 patients with Stage III disease received
the same radiation treatment schedule i.e., EBRT was de-
livered to a dose of 50 Gy in 25 fractions of two Gy each,
five fractions per week for 5 weeks. Brachytherapy boost
dose was 21 Gy given in six fractions of 3.5 Gy each, twice
daily at 6 hours apart, given within two to four weeks of
Table 2 Overall treatment outcome
Distribution Number Percent
Complete response 28 84.84
Residual disease 5 15.15
Expired due to cancer progression 1 3.03
Expired (Total) 1 3.03
Vedasoundaram et al. SpringerPlus 2014, 3:590 Page 3 of 8
http://www.springerplus.com/content/3/1/590EBRT with addition of two cycles of Injection Cisplatin
at 70 mg/m2 in three divided dose, three weeks apart,
concurrently with EBRT. Node positive patients received
brachytherapy boost for dose of 21Gy in 6 fractions.
For external beam radiation all patients were positioned
supine, immobilized with head rest and thermoplastic
mask. Simulation was done in Varian Acuity 2-D simulator.
Radiation was delivered by conventional 2-D technique
with antero-lateral wedged pair fields using 6MV photons,
in Clinac600C Linear Accelerator.
After proper evaluation, brachytherapy procedure was
done under general anesthesia. Flexible catheters were
placed as double plane implant. A non-contrast planning
CT scan of the implanted region with one millimeter
thick slices was taken on the second day after the pro-
cedure using Somatom Spirit (Siemens) CT. The images
were then transferred to the treatment planning systems,
either Brachy Vision (Varian Medical Systems, Palo Alto,
CA) or Oncentra Master Plan (Nucletron, BV). The Clin-
ical Target Volume (CTV) was delineated and the applica-
tors reconstructed. A reference point was inserted at
the tip of all the applicators. Dose optimization was
done by adjusting dwell times in individual dwell posi-
tions to ensure that at least 90 percent of the CTV
received the prescribed dose. AAPM TG-43 formalism
was used to generate the dose distributions. Cumulative
Dose Volume Histogram (DVH) was used to study the
dosimetric parameters.
Follow-up
Patients were followed up every 2 months in the first year,
every 3 months in the second year and every 4 months
thereafter, for a period of 12 months to 60 months.
Statistical analysis
Profile of baseline characteristics and stage and treatment
based patient distributions are presented as frequencies
and percentages. Dose parameters are expressed as means.
Subgroup analysis of treatment outcomes were done with
Pearson’s Chi square test and Fisher’s exact test. Analysis
of dose parameters and toxicities was done using Binary
Logistic regression analysis and Spearman’s correlation
test. 5% level of significance was used for all statistical
tests and a p-value of < 0.05 was considered statistically
significant. SPSS software (version 20) was used for the
analysis.
Ethical considerations
Informed consent was obtained from all participants after
proper explanation of the treatment procedure in their
vernacular language. Ethical clearance was obtained from
competent authority.
Ethical committee clearance was obtained vide number
SEC/2011/4/101, approved on 30/11/2011.Results
A total of 33 patients were recruited for the study from
November 2008 to April 2013. The baseline characteris-
tics are summarized in Table 1.
There were five patients (15.15%) with Stage I disease,
13 patients (39.4%) with Stage II and 15 (45.45%) with
Stage III disease. Five patients (15.15%) had node positive
(N1) disease. 13 patients (39.39%) with Stage II received
external beam radiation and brachytherapy boost. 15
patients (45.45%) with Stage III disease received external
beam radiation and brachytherapy boost with Injection
Cisplatin 70 mg/m2 given concurrently with external
beam radiation. 31 patients (94%) had one or more of
these habits including alcohol intake
Table 2 shows the overall outcome of the treatment.
28 patients (84.84%) had complete response. Figures 1,
2, 3, 4 and 5 shows the pretreatment evaluation, treat-
ment and post treatment follow-up of one patient; who
is disease free till date. Five patients (15.15%) had
residual disease. All patients with residual disease were
referred to surgical oncology department for salvage
surgery. Four patients had good salvage surgery and
had no further events during the follow-up period. One
patient progressed after surgery and was given palliative
chemotherapy with Injection Cisplatin and Paclitaxel.
But the disease progressed and ultimately the patient
succumbed to the disease.
Table 3 shows the local response rates in relation
to the disease Stage. 5/5 patients (100%) with Stage I
disease had complete response. Rates of complete re-
sponses were lower with Stage II and Stage III diseases
but the differences among the groups were not statisti-
cally significant. Sub group analysis showed no statisti-
cally significant difference in treatment outcomes with
respect to gender, disease growth characteristics or pa-
tient’s habits like smoking, tobacco chewing, betel chew-
ing, etc.,.
Table 4 displays the means of various Brachytherapy
indices. Coverage Index (CI), Dose Homogeneity Index
(DHI), Dose-Non uniformity Ratio (DNR), Conformal
Index (COIN), External Volume Index (EVI) were calcu-
lated to know about the CTV coverage of implant and to
assess the effect of these indices on local control and
toxicities related to brachytherapy boost. The above indi-
ces did not show any statistically significant differences
Figure 1 Pre-treatment gross tumor seen in Left Buccal mucosal carcinoma.
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Spearman’s correlation.
Brachytherapy indices like Coverage Index (CI), Dose
Homogeneity Index (DHI), Dose-Non uniformity Ratio
(DNR), Conformal Index (COIN) and External Volume
Index (EVI) were calculated in this study and compared
with the reference dose (Feuvret et al. 2006; Kehwar
et al. 2008). These indices rely on 3D image-based ap-
proach and volume based optimization. In this study
Clinical Target Volumes were contoured and dose was
prescribed to the isodose covering the target (Mazeron
et al. 2009).
Clinical Target Volume covered by 200%, 150%, 100%
and 90% of isodoses did not show any statistically
significant differences in local control based on Logistic
regression analysis and Spearman’s correlation.
Tables 5 shows the various acute and late toxicities
observed in these patients. Toxicities where graded using
Radiation Therapy Oncology Group (RTOG) criteria (CoxFigure 2 Interstitial implant procedures done in Left Buccal mucosalet al. 1995). Acute mucositis and skin reactions were the
most common acute radiation toxicities which occurred
in approximately 80% of the patients. There was one grade
3 skin reaction which required a brief treatment interrup-
tion. Acute nausea and vomiting were observed in about
40% and 24% of patients respectively, commonly in pa-
tients on concurrent chemo radiation. Only one patient
had soft tissue necrosis.
Discussion
With invention of newer technologies and highly con-
formal dose delivery, modern radiotherapy has set a high
standard for the management of oral cavity cancers. The
ability to preserve normal anatomy and provide better
cosmetic and functional outcomes has made radiother-
apy an effective alternative to surgery, which has been
the gold standard for management of both early and lo-
cally advanced oral cavity cancers from time immemorial
(Matsui et al. 2007). Three Dimensional ConformalCarcinoma.
Figure 3 Interstitial implants connected to HDR after loading catheters.
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therapy (IMRT) have made possible higher dose delivery
with curative intent to the tumor, with acceptably lower
doses to normal organs and critical structures in its neigh-
borhood (Studer et al. 2007). However, higher costs and
complexity in planning and treatment delivery have pre-
cluded their widespread adoption, especially in third world
nations, where cost effectiveness and ease of implementa-
tion are the need of the hour (Nijdam et al. 2008).
Brachytherapy has proven itself indispensable in the
management of specific cancers like cancer cervix and
oral cavity cancers over the decades, as a primary modal-
ity or as a boost. Its lower cost and simplicity, coupled
with its ability to provide high localized dose with rapid
dose fall off has made it an excellent tool to provide
conformal therapy in these cancers, with minimal side
effects compared to EBRT. A study by Sresty et al.
(2010) showed that interstitial brachytherapy conferred
more dose homogeneity when compared with IMRT and
lesser dose to critical structures. Also planning time was
much less for most cases. It concluded that interstitial
brachytherapy was an ideal option for high dose deliveryFigure 4 CTV and Dose colourwash in left Buccal mucosal Carcinomaexclusively to the primary tumor volume, while limiting
the risk of severe xerostomia or trismus.
From the present study we can infer that HDR Intersti-
tial brachytherapy alone is a viable option for management
of small localized buccal mucosal cancers. Five patients
with T1N0 tumors were treated with HDR brachytherapy
alone to a dose of 38.50 Gy and all of them had complete
response at the end of treatment and continued progres-
sion free throughout the follow up period.
The extent of the primary lesion and the presence of
nodal disease were found to have an impact on the local
control. Patients with Stage I disease had 100% local
control whereas Stage II and III patients had 84.6% and
80% local control respectively. This outcome is similar
to other published results (Hiratsuka et al. 1997; Shear
et al. 1976). Survival following primary surgery for oral
cancer showed similar statistics (Simon et al. 2009).
Most of the published literatures in interstitial brachy-
therapy for oral cavity cancers were based on LDR and
manual after loading techniques (Conill et al. 2007). With
the recent advances in 3D image based techniques, the
possibility of accurate delineation of the target volumesshowing adequate target volume coverage.
Figure 5 Complete response seen in left Buccal mucosal carcinoma after completion of treatment on follow up.
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brachytherapy much safer to patients and disease control
better (Harrison 1997; Strnad 2004).
According to the American Brachytherapy Society rec-
ommendations Coverage Index of 1, Dose Homogeneity
Index of more than 0.75 and External Volume Index of
zero (EVI = 0) should be achieved with more than 90%
of dose delivered to >90% target volume. Nag et al.
(2001) stated that Conformal index (COIN) should be
one (1) in order to achieve better quality of tumor irradiation
and normal tissue sparing by interstitial brachytherapy.
In this study group the mean Coverage Index was 0.87
(ideal 1), Dose Homogeneity Index 0.7 (ideal 0.75),
Dose-Non uniformity Ratio 0.3 (ideal 0.1), Conformal
Index 0.84 (ideal 1) and External Volume Index 0.03
(ideal 0.05). All the parameters were well within the
recommended range.
Patients with near ideal Coverage Index and Conformity
Index showed a trend to complete response compared to
those with residual disease. However Logistic Regression
Analysis showed that these trends did not graduate to
statistical significance. There were no observable differ-
ences with other indices with respect to the disease
response. Still, we can observe from this study that good
brachytherapy technique definitely plays a role in obtain-
ing complete response.Table 3 Comparison of treatment outcome in relation to stag
Outcome Stage I Stage II
Number % Number
Complete response 5 100 11
Residual disease 0 0 2
Total 5 100 13
Pearson's Chi squareTobacco chewing, smoking and betel nut chewing are
known to be significant factors in the etiopathogenesis
of oral cavity cancers (Llewellyn et al. 2001). In this study
sample, 31 patients (94%) had one or more of these habits
including alcohol intake. However in subgroup analysis,
neither of these habits individually correlated with the dis-
ease outcome. Similarly, no correlation to disease outcome
was observed with the histological grade or the morpho-
logical growth pattern of the tumor.
The treatment was well tolerated by most patients.
The most common side effects observed during radiation
were acute mucositis and skin reactions (80% of patients).
50% had grade I toxicities and 30% had grade II. All of
them were managed conservatively with antiseptic oral
rinses and zinc containing multivitamins which improved
the symptoms. One patient had grade III skin reaction
during external beam radiation and radiation had to be
briefly interrupted to allow healing (Emami et al. 1991).
Patients with locally advanced diseases were given concur-
rent Cisplatin chemotherapy with external beam radiation
followed by brachytherapy boost (15 patients, 45%) after
two weeks of EBRT. Acute nausea and vomiting were
observed in 40% and 24% of these patients and were
managed effectively with antiemetics.
Six patients (18%) developed grade II neutropenia
following chemotherapy and were managed with regulare
Stage III Total p value
% Number %
84.6 12 80 28 0.6
15.4 3 20 5
100 15 100 33
1.2
Table 4 Brachytherapy indices
Indices CR R
Mean SD Mean SD
CI 0.874851 0.053707 0.750564 0.014628
DHI 0.682676 0.090335 0.696503 0.04411
DNR 0.317324 0.090335 0.303497 0.04411
EVI 0.032005 0.013143 0.09421 0.052554
COIN 0.844155 0.056749 0.668754 0.029791
Abbreviations: CR complete response, R residual disease, CI Coverage index,
DHI Dose Homogeneity index, COIN conformal index, DNR Dose Non uniformity Ratio,
EVI-external volume index, SD- Standard deviation.
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necessary. Few patients had treatment interruptions and
delay in brachytherapy due to these acute toxicities
(8 patients). However, there was no statistically sig-
nificant effect on the local control with these delays.
8 month after completion of treatment one patient de-
veloped soft tissue necrosis. She was managed conserva-
tively with analgesics and antibiotics. She was symptom
free after six months of close follow up period (Emami
et al. 1991).
Conclusion
Surgery with or without adjuvant radiotherapy has been
the standard of treatment for buccal mucosal cancers.
Most of the buccal mucosal cases are operated by Surgeons.Table 5 Toxicities observed during ebrt/ccrt and on
follow up
Acute toxicities N %








Acute nausea NO 20 60.6
YES 13 39.39
Acute vomiting G0 25 75.75
G1 7 21.21
G2 1 3.03
G2 Neutropenia NO 27 81.81
YES 6 18.18
Late toxicity
Soft tissue necrosis 1 3.03
Death 1 3.03
Abbreviations: N number, % percentage, G grade.Number of early buccal mucosal cases reported to
Radiation Oncology department is small. We can say
from the study that EBRT with brachytherapy boost
can produce survival rate and local control comparable to
surgery alone (Simon et al. 2009). With lower morbidity,
better cosmetic and functional outcomes and comparable
local control and survival rates, radiotherapy has slight ad-
vantage over surgery in early and locally advanced buccal
mucosal lesions. Good brachytherapy technique and me-
ticulous planning are essential to ensure adequate dose
coverage of the tumor. Well planned multiple plane im-
plants with adequate equally spaced flexible catheters will
give more room for uniform dose delivery and translate
to near ideal brachytherapy indices and better treatment
outcomes.
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